Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sulfadoxine + pyrimethamine + artesunate
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Sulfadoxine + pyrimethamine + artesunate is a fixed-dose combination antimalarial therapy used primarily for the treatment of uncomplicated malaria caused by Plasmodium falciparum. This combination is classified as an artemisinin-based combination therapy (ACT) and is recommended by the World Health Organization (WHO) for areas with chloroquine resistance[3][6]. Artesunate is a semi-synthetic derivative of artemisinin that rapidly reduces parasite biomass through production of reactive metabolites. Sulfadoxine and pyrimethamine are folic acid antagonists; sulfadoxine inhibits dihydropteroate synthase while pyrimethamine inhibits dihydrofolate reductase, resulting in sequential blockade of folate synthesis in the parasite[5][6]. The synergy between these drugs enhances efficacy and helps delay resistance development. The regimen typically involves once-daily dosing of artesunate for three days with a single dose of sulfadoxine-pyrimethamine on day one[1][3].
- Brand names
- Artiscope kitLarinateFalciart Kit
- Other names
- artesunate + sulfadoxine/pyrimethamineAS+SP
02
Targets
DHFR (Dihydrofolate reductase)DHPS (Dihydropteroate synthase)β-Hematin
Beyond the preview
Go deeper on sulfadoxine + pyrimethamine + artesunate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sulfadoxine + pyrimethamine + artesunate.